Conclusion-Recommendation: All hospitalized patients with COVID-19 should at least receive timely prophylactic anticoagulation. In the case of high risk for bleeding/active bleeding, mechanical prophylaxis should be used. In high thrombotic risk, non-critically ill (non-ICU) patients, a therapeutic dose of heparin (LMWH/UFH) is recommended, taking into consideration the individual patient’s bleeding risk. The role of the intermediate dose heparin in such patients has not been adequately studied in RCTs. For critically ill (ICU) patients, higher dosages do not offer a benefit and increase the bleeding risk; therefore, a prophylactic dosage should be administered, preferably with LMWH/UFH.